Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: A review and meta-analysis

Medicine

Volumn 89, Issue 4, 2010, Pages 236-244

  Safdar, Amar ^a   Ma, Jonathan ^b   Saliba, Fouzi ^c   Dupont, Bertrand ^d   Wingard, John R ^e   Hachem, Ray Y ^a   Mattiuzzi, Gloria N ^a   Chandrasekar, Pranatharthi H ^f   Kontoyiannis, Dimitrios P ^a   Rolston, Kenneth V ^a   Walsh, Thomas J ^g   Champlin, Richard E ^a   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c HÔPITAL PAUL BROUSSE   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ASPERGILLOSIS; CHILL; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LIVER TOXICITY; LUNG INFECTION; META ANALYSIS; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY FAILURE, ACUTE;

EID: 77954751954     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e3181e9441b     Document Type: Review

References (34)

1. Andes D, Safdar N, Marchillo K, Conklin R. Pharmacokinetic- pharmacodynamic comparison of amphotericin B (AmB) and two lipid-associated AmB preparations, liposomal AmB and AmB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother. 2006;50:674-684.
2. Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol. 2003;41:5525-5529.
3. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R. Mortality and cost of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32:686-693. (Pubitemid 32221925)
4. Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy. 2001;21:1107-1114.
5. Couch K, Chan S, Cincotta E, Piper JP, Forrest G. Comparative nephrotoxicity, adverse events, and clinical outcomes of lipid associated amphotericin B products. (Abstract P-047.) The 13th Focus on Fungal Infections; Maui, Hawaii; March 19-21, 2003.
6. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother. 2002;49(Suppl 1):37-41. (Pubitemid 34162655)
7. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis. 2000;30:653-657.
8. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002;49(Suppl 1):31-36.
9. Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, Pierce S, Cortes J, Estey E. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001;40:511-520.
10. Groll AH, Lyman CA, Petraitis V, Petraitiene R, Armstrong D, Mickiene D, Alfaro RM, Schaufele RL, Sein T, Bacher J, Walsh TJ. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother. 2006;50:3418-3423.
11. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive Aspergillosis in patients with hematologic malignancy. Cancer. 2008;112:1282-1287.
12. Hoitsma AJ, Wetzels JF, Koene RA. Drug-induced nephrotoxicity. Aetiology, clinical features and management. Drug Saf. 1991;6:131-147.
13. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350-1360.
14. Larabi M, Legrand P, Appel M, Gil S, Lepoivre M, Devissaguet J, Puisieux F, Barratt G. Reduction of NO synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers. Antimicrob Agents Chemother. 2001;45:553-562.
15. Lewis RE, Albert ND, Hou J, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex (ABLC) and liposomal amphotericin B (L-AMB) in a murine model of acute invasive pulmonary zygomycosis. (Abstract M-2139.) 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Infectious Diseases Society of America (IDSA); Washington, DC; October 25-28, 2008.
16. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2007;51:1253-1258.
17. Lopez Sastre JB, Coto Cotallo GD, Fernandez Colomer B. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol. 2003;20:153-163.
18. Malani PN, Depestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA. Experience with community-based amphotericin B infusion therapy. Pharmacotherapy. 2005;25:690-697.
19. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917. (Pubitemid 34229758)
20. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100:581-589. (Pubitemid 38124777)
21. McKechnie M, Rotstein C, McTaggart B. A multi-center, retrospective comparison of the nephrotoxicity effects of amphotericin B lipid complex and liposomal amphotericin B. (Abstract P-048.) The 13th Focus on Fungal Infections; Maui, Hawaii; March 19-21, 2003.
22. Nucci M, Marr KA, Queitoz-Telles F, Martins CA, Trabasso P, Costa S, Voltarelli JC, Colombo AL, Imhof A, Pasquini R, Maiolino A, Souza CA, Anaissie E. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237-1242.
23. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard''. Clin Infect Dis. 2003;37:415-425.
24. Pathak A, Pien FD, Carvalho L. Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis. 1998;26:334-338.
25. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concerns for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42:4419-4431.
26. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653.
27. Safdar A. Difficulties and healthcare utilization/cost associated with the management of fungal infections in patients with acute myelogenous leukemia. Clin Advan Hematol Oncol. 2008;6(Suppl 12):4-10.
28. Saliba F, Cheron N, Ichai Ph, Renault A, Sirvent A, Depil S, Saulquin B, Witz B, Visanca S, Bastien O, Guillaumin S. A prospective French National Survey to assess renal safety of amphotericin B lipid complex and liposomal amphotericin B. (Abstract 123.) Int J Infect Dis. 2006; 10(Suppl 1):S68-S69.
29. Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol. 2008;46:97-112.
30. Simitsopoulou M, Roilides E, Dotis J, Dalakiouridou M, Dudkova F, Andreadou E, Walsh TJ. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother. 2005;49:1397-1403.
31. Slain D, Miller K, Khakoo R, Fisher M, Wierman T, Jozefczyk K. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a University Hospital: a retrospective study. Clin Ther. 2002;24:1636-1642.
32. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46:327-360.
33. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383-1396.
34. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000; 31:1155-1163.